Aastrom Biosciences, Inc. Enters Into $15 Million Equity Commitment With Lincoln Park Capital

Published: Jan 27, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ANN ARBOR, Mich., Jan. 27, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announced today that it has entered into a stock purchase agreement with Lincoln Park Capital Fund, LLC ("Lincoln Park"), an institutional investor. Under the terms of the agreement, Aastrom has the right to sell up to $15 million in shares of common stock to Lincoln Park over a thirty-month period subject to certain limitations and conditions set forth in the purchase agreement.

Help employers find you! Check out all the jobs and post your resume.

Back to news